Arterionephrosclerosis
MONDO:0980737A chronic kidney disease that is characterized by arteriosclerosis, global glomerulosclerosis, and cortical fibrosis with tubular atrophy and loss.
18 clinical trials for this condition and its sub-types.
Follow this condition — get notified about new trialsBroader categories
-
Can a peer coach help young people take control of their chronic illness?
Disease control CompletedThis study tests whether a peer coaching program delivered by phone and text can help adolescents and young adults (ages 16–22) with chronic conditions like sickle cell disease, diabetes, or cystic fibrosis improve their self-management skills. Participants are paired with a trai…
Phase: NA • Sponsor: Duke University • Aim: Disease control
Last updated Jul 19, 2026 00:00 UTC
-
Aging kidneys under the microscope: could a simple test predict failure?
Knowledge-focused CompletedThis study looks at thousands of Chinese adults aged 60 and older to understand how kidney function changes with age. Researchers are examining a range of blood and urine markers to see which ones best predict kidney failure, heart problems, and death. They are also testing diffe…
Sponsor: Huashan Hospital • Aim: Knowledge-focused
Last updated Aug 16, 2026 00:00 UTC
-
Contrast dye Double-Dose: new study tracks kidney fallout in ICU patients
Knowledge-focused CompletedThis study follows 112 critically ill patients with pre-existing kidney disease who receive one or two doses of contrast dye for imaging. Researchers track kidney function, including acute injury and long-term decline, over six months. The goal is to understand how repeated contr…
Sponsor: Cairo University • Aim: Knowledge-focused
Last updated Jul 23, 2026 00:00 UTC
-
New drug tested in kidney patients: how does it behave?
Knowledge-focused CompletedThis study looks at how the body handles a new drug called S-892216 in people with mild, moderate, or severe kidney problems, including those on dialysis, compared to people with healthy kidneys. About 40 adults will take a single dose of the drug, and researchers will measure it…
Phase: PHASE1 • Sponsor: Shionogi • Aim: Knowledge-focused
Last updated Jul 15, 2026 00:00 UTC